Effect of melatonin (50 μM) on the TGF-β1 (10 ng/mL, 72 h)-mediated TGF-β1/Smad pathway and EMT in HBdSMCs. by Yang Zhang (30734)

Dynamic characteristics of (A) FIB and (B) PCT between the survival and deceased groups of SFTS patients with HLH. by Bo Zhang (6559)

Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

The concentrations of VEGFA secreted from the vertebral endplate during organ culture (ng/L, n = 4, x ± s). by Jia-Wen Zhan (9028652)

Fig 5 - by Andrea R. Thurman (5286005)

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

DataSheet_1_Mono-(2-ethylhexyl) phthalate Promotes Dengue Virus Infection by Decreasing IL-23-Mediated Antiviral Responses.pdf by Chun-Yu Lin (414543)

“…Among 89 DV-infected patients, those with DV infection-related gastrointestinal (GI) bleeding (n = 13, 15% of patients) had significantly higher DEHP exposure than those without GI bleeding (n = 76, 85% of patients), which were 114.2 ng/ml versus 52.5 ng/ml ΣDEHP in urine; p = 0.023). …”

DataSheet_2_Mono-(2-ethylhexyl) phthalate Promotes Dengue Virus Infection by Decreasing IL-23-Mediated Antiviral Responses.docx by Chun-Yu Lin (414543)

“…Among 89 DV-infected patients, those with DV infection-related gastrointestinal (GI) bleeding (n = 13, 15% of patients) had significantly higher DEHP exposure than those without GI bleeding (n = 76, 85% of patients), which were 114.2 ng/ml versus 52.5 ng/ml ΣDEHP in urine; p = 0.023). …”

Changes in blood pressure before, during and after regadenoson (RA) infusion. by Joseph Rabin (7399436)

Subjects:

Diagram showing some of the factors that mediate cytokin storm following infection with COVID-19. by Joseph Rabin (7399436)

Subjects:

Antibodies used for flow cytometry experiments. by Joseph Rabin (7399436)

Subjects:

Changes of plasma proinflammatory cytokines/chemokines during and after RA infusion. by Joseph Rabin (7399436)

Subjects:

Demographics of the COVID-19 patients who received regadenoson treatment. by Joseph Rabin (7399436)

Subjects:

Subject flow diagram. by Joseph Rabin (7399436)

Subjects:

Effects of regadenoson (RA) infusion on oxygen saturation and C-reactive protein (CRP) levels in plasma of COVID-19 patients. by Joseph Rabin (7399436)

Subjects:

<b>Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons</b> by Muhammad Saad Yousuf (20745168)

Summary of findings table for the comparison of remdesivir 5 days vs. remdesivir 10 days for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)